The University of Michigan Comprehensive Cancer Center received a $1.65 million gift from the Hirair and Anna Hovnanian Foundation to fund adrenal cancer research.
In a randomized phase 3 trial, adrenal cancer patients receiving the investigational drug linsitinib fared no better than patients receiving a placebo. But the researchers noticed a small subset of patients who had significant response and remained on the drug for an extended time.
Researchers used the proton pump inhibitor omeprazole, a commonly used acid inhibitor, in combination with naproxen and found it was effective at preventing bladder cancer in an animal model.
Theodore S. Lawrence, M.D., Ph.D., has been named the director of the University of Michigan Comprehensive Cancer Center. Lawrence, who is also chair of radiation oncology, succeeds founding director Max S. Wicha, M.D.
Uterine sarcoma was found in 0.22% of women following a hysterectomy for benign conditions, a new study finds. This may have implications for the risks associated with controversial power morcellation procedures.
A new study provides direct evidence for the role of the Notch pathway in breast cancer stem cell activity as demonstrated by a Notch reporter system. Notch signaling regulates embryonic and tissue-specific stem cells, which are altered in a number of cancers, including breast cancer.
A set of guidelines developed to help standardized lung cancer screening would have generated considerably fewer false-positives than the National Lung Screening Trial produced, according to a new retrospective study.
The Centers for Medicare and Medicaid Services have finalized coverage guidelines for lung cancer screening with CT scans for people at high-risk of developing lung cancer. Coverage goes into effect immediately.
A new study from researchers at the University of Michigan Comprehensive Cancer Center sheds light on the KRAS pathway with a potential target that might have more success at stopping lung cancer growth.
Researchers at the University of Michigan Comprehensive Cancer Center have received a grant from the Lustgarten Foundation worth $1.5 million for a project focused on using a pancreatic cancer patient's blood sample to determine the best treatments.